Navigation Links
Molecular link between diabetes and cancer described
Date:11/15/2011

Developing type 2 diabetes is a lengthy process. An early sign that it has begun is high levels of insulin in the blood. As long as the insulin-producing beta cells are able to compensate for the increased demand, for example when the individual is overweight, the blood sugar levels remain normal. It is not until the capacity for insulin secretion falls below the level needed that type 2 diabetes becomes a fact. The latter stage generally goes quickly, as the stressed beta cells work themselves to death.

"We have worked with the most well-known risk gene for type 2 diabetes, a variant of the TCF gene, and have studied its function in the beta cells", says Yuedan Zhou, a doctoral student at the Lund University Diabetes Centre and principal author of the published study.

The risk variant of TCF is common, 25 per cent of the population carry it and 31 per cent of diabetics, according to figures from the Malm Preventive Project population survey.

An equally well-established risk gene in cancer research is p53. The gene has been called the "protector of the genome" because it prevents the uncontrolled cell division that takes place in cancer. The p53 gene has been linked to protection against colon and liver cancer, among others.

"The function of the TCF gene in the beta cells is to protect the cells against high, stressful blood sugar levels. If that function fails, the beta cells die, which leads to diabetes", says Ola Hansson, researcher and principal author of the survey.

The two genes work in concert, TCF protects against cell death, while p53 prevents excessive cell division.

"It is here that the connection between diabetes and cancer arises. When the blood sugar levels are high, the TCF gene is activated and this impedes the activity of the p53 gene thereby protecting the beta cells from cell death" .

The research group began working with the TCF gene two years ago to understand its role in insulin production. The discovery of the link with p53 and cancer was mostly by chance.

"Or good intuition", they say.

The mapping of the TCF gene is continuing, this time in collaboration with the European Bioinformatics Institute in Cambridge.

Cancer researchers are working to try and influence p53 so that its tumour-preventing function is restored.

"In a similar way, strengthening the protective function of TCF against beta cell death in connection with high blood sugar would work as a drug for type 2 diabetes, or as a treatment before the disease has even developed fully", says Ola Hansson.


'/>"/>

Contact: Ola Hansson
Ola.Hansson@med.lu.se
46-739-549-923
Lund University
Source:Eurekalert

Related medicine news :

1. AACR-NCI-EORTC to hold molecular targets meeting in San Francisco
2. Nobel Laureate Bruce Beutler on molecular sensors as a trigger for autoimmune disease
3. Biodesign researchers to develop new reagent pipeline for molecular medicine
4. Molecular depth profiling modeled using buckyballs and low-energy argon
5. New equation predicts molecular forces in hydrophobic interactions
6. AACR hosts molecular targets and cancer therapeutics conference
7. Researchers identify potential molecular target to prevent growth of cancer cells
8. New clues to molecular understanding of autism
9. Molecular meet and greet
10. Hebrew U. scientists identify molecular basis for DNA breakage
11. Blocking molecular target could make more cancers treatable with PARP inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... ... On Tuesday, April 26, 2016 members of the HomeTown Health network, a ... Deal on SB 258, the “Rural Health Care Relief” Bill. , The bill, which ... to individuals and corporations which donate directly to a “rural hospital” in Georgia, and ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
(Date:4/29/2016)... ... 2016 , ... Mobility Designed is redefining mobility with their patent pending ... Crutch evenly distributes body weight from the elbow to the forearm. In consumer ... than with other crutches. , Co-founders Max and Liliana Younger were inspired to design ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
Breaking Medicine Technology: